<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6110">
  <stage>Registered</stage>
  <submitdate>5/12/2014</submitdate>
  <approvaldate>5/12/2014</approvaldate>
  <nctid>NCT02312258</nctid>
  <trial_identification>
    <studytitle>A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation</studytitle>
    <scientifictitle>A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>U1111-1160-1702</secondaryid>
    <secondaryid>C16021</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ixazomib
Treatment: drugs - Placebo

Experimental: Ixazomib - Ixazomib 3 mg, capsule, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.

Placebo Comparator: Placebo - Ixazomib placebo-matching 3 mg capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib placebo-matching 3 or 4 mg capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study, but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.


Treatment: drugs: Ixazomib
Ixazomib capsules

Treatment: drugs: Placebo
Ixazomib placebo-matching capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - PFS is defined as the time from the date of randomization to the date of first documentation of disease progression, as evaluated by an independent review committee according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first.</outcome>
      <timepoint>Every 28 days up to 24 months and every 4 weeks during follow-up until progressive disease on next line therapy (Up to 88 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - OS will be measured as the time from the date of randomization to the date of death.</outcome>
      <timepoint>Every 28 days from the Randomization date to progressive disease on next line therapy and every 12 weeks during follow up afterwards (Up to 88 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants who Achieve or Maintain Any Best Response Category during the Treatment Period - Response will be assessed according to IMWG criteria. Best response includes partial response (PR), very good partial response (VGPR) and complete response (CR).</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Progression (TTP) - TTP is defined as the time from the date of randomization to the date of first documentation of progressive disease, using IMWG criteria.</outcome>
      <timepoint>From the date randomization to the date of first documented progressive disease (Up to 88 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Second Progression-Free Survival (PFS2) - PFS2 is defined as the time from the date of randomization to objective disease progression on next-line treatment using IMWG criteria, or death due to any cause, whichever occurs first.</outcome>
      <timepoint>Every 12 weeks from the randomization to 2nd disease progression or death (Up to 88 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to End of the Next Line of Therapy after Study Treatment - Time to end of the next line of therapy is defined as the time from the date of randomization to the date of last dose of the next line of antineoplastic therapy following study treatment or death due to any cause, whichever occurs first.</outcome>
      <timepoint>From the randomization to the date of last dose of the next line of therapy (Up to 88 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Develop A New Primary Malignancy</outcome>
      <timepoint>From the randomization date till death or termination of the study (Up to 88 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Conversion from Minimal Residual Disease (MRD) Positive to MRD Negative, or the Maintenance of MRD Negativity - Bone marrow aspirates and blood samples will be sent to a central laboratory and will be assessed for MRD using flow cytometry and a sequencing methodology. MRD negativity is defined as absence of MRD and MRD positivity is defined as presence of MRD.</outcome>
      <timepoint>Screening, Cycle 13 (± 2 cycles), and Cycle 26 (± 2 cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall (OS) Survival in a High-Risk Population - High-risk population will include but not be limited to participants carrying deletion (del)17, t(4:14), t(14:16), amplification (ampl) 1q, del13, or del1p. OS will be measured as the time from the date of randomization to the date of death.</outcome>
      <timepoint>From randomization up to 88 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) in a High-Risk Population - High-risk population will include but not be limited to participants carrying deletion (del)17, t(4:14), t(14:16), amplification (ampl) 1q, del13, or del1p. PFS is defined as the time from the date of randomization to the date of first documentation of disease progression.</outcome>
      <timepoint>Screening, Day 1 of each cycle; End of Treatment and then every 4 weeks until disease progression (Up to 88 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Serious Adverse Events and Adverse Events (AEs) - A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug.</outcome>
      <timepoint>First dose of study drug through 30 days after last dose of study drug (Up to 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) QLQ-C30 - The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) QLQ-C30 is completed by the patient. The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The patient answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7= Excellent (best).</outcome>
      <timepoint>Baseline and every 28 days (Up to 24 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Any Markedly Abnormal Standard Safety Laboratory Values - Clinical laboratory evaluations will be performed by a central laboratory. The number of participants with any markedly abnormal standard safety laboratory values collected throughout study.</outcome>
      <timepoint>From First dose date of study drug through 30 days after the last dose of study drug (Up to 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between Frailty Status and Progression Free Survival (PFS) and Overall Survival (OS)</outcome>
      <timepoint>Up to 88 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic Parameter: Plasma Concentration of Ixazomib - Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) will be measured using a validated Liquid Chromatography-tandem Mass Spectrometry (LC/MS/MS) assay.</outcome>
      <timepoint>Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3,4,6-10 (Day 1 pre-dose)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Resolution of Peripheral Neuropathy (PN) Events - Peripheral neuropathy (PN) is defined as the treatment-emergent adverse event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the Medical Dictionary for Regulatory Activities (MedDRA). A PN event is considered as resolved if its final outcome is resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after.
Time to resolution is defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.</outcome>
      <timepoint>From randomization date through 30 days after the last dose of drug (Up to 25 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Improvement of Peripheral Neuropathy (PN) Events - Peripheral neuropathy (PN) is defined as the treatment-emergent adverse event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the Medical Dictionary for Regulatory Activities (MedDRA). A PN event is considered as resolved if its final outcome is resolved with no subsequent PN event of the same preferred term occurring on the improvement date or the day before and after.
Time to improvement is defined as the time from the initial onset date (inclusive) to the improvement of event.</outcome>
      <timepoint>From randomization date through 30 days after the last dose of drug (Up to 25 Months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Adult male or female participants 18 years or older with a confirmed diagnosis of
             symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.

          2. Completed 6 to 12 months (± 2 weeks) of initial therapy, during which the participant
             was treated to best response, defined as the best response maintained for 2 cycles
             after the M-protein nadir is reached.

          3. Documented major response [partial response (PR), very good partial response (VGPR),
             complete response (CR)] according to the International Myeloma Working Group (IMWG)
             uniform response criteria, version 2011, after this initial therapy.

          4. Female participants who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the participant. (Periodic abstinence (eg, calendar,
                  ovulation, symptothermal, postovulation methods] and withdrawal are not
                  acceptable methods of contraception.)

             Male participants, even if surgically sterilized (ie, status postvasectomy), who:

               -  Agree to practice effective barrier contraception during the entire study
                  Treatment period and through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the participant. (Periodic abstinence [eg, calendar,
                  ovulation, symptothermal, postovulation methods for the female partner] and
                  withdrawal are not acceptable methods of contraception.)

          5. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the participant at any time without prejudice to future medical care.

          6. Complete documentation of the details of the initial therapy before randomization
             including cytogenetics and International Staging System (ISS) is available.

          7. Eastern Cooperative Oncology Group Performance Status of 0 to 2.

          8. Suitable venous access for the study-required blood sampling and consent for the
             specific amounts that will be taken.

          9. Is willing and able to adhere to the study visit schedule and other protocol
             requirements including blood sampling and bone marrow aspiration.

         10. Must meet the following clinical laboratory criteria at study entry:

               -  Absolute neutrophil count (ANC) = 1,000/mm^3 without growth factor support and
                  platelet count = 75,000/mm^3. Platelet transfusions to help participants meet
                  eligibility criteria are not allowed within 3 days before randomization.

               -  Total bilirubin = 1.5 x the upper limit of the normal range (ULN).

               -  Alanine aminotransferase and aspartate aminotransferase = 3 x ULN.

               -  Calculated creatinine clearance = 30 mL/min (using the Cockcroft-Gault equation).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Multiple myeloma that has relapsed after, or was not responsive to, initial therapy.

          2. Prior stem-cell transplantation (SCT).

          3. Radiotherapy within 14 days before randomization.

          4. Diagnosed or treated for another malignancy within 5 years before randomization or
             previous diagnosis with another malignancy. Participants with nonmelanoma skin cancer
             or carcinoma in situ of any type are not excluded if they have undergone complete
             resection.

          5. Female participants who are lactating and breastfeeding or have a positive serum
             pregnancy test during the Screening period.

          6. Major surgery within 14 days before randomization.

          7. Central nervous system involvement.

          8. Infection requiring intravenous (IV) antibiotic therapy or other serious infection
             within 14 days before randomization.

          9. Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly,
             endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell
             leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative
             syndrome.

         10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

         11. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin,
             ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin,
             itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole), or strong CYP3A
             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital)
             or use of Ginkgo biloba or St. John's wort within 14 days before randomization.

         12. Ongoing or active infection, known human immunodeficiency virus positive, active
             hepatitis B or C infection.

         13. Comorbid systemic illnesses or other severe concurrent disease that, in the judgment
             of the investigator, would make the participant inappropriate for entry into this
             study or interfere significantly with the proper assessment of safety and toxicity of
             the prescribed regimens (eg, peripheral neuropathy (PN) that is Grade 1 with pain or
             Grade 2 or higher of any cause).

         14. Psychiatric illness/social situation that would limit compliance with study
             requirements.

         15. Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

         16. Inability to swallow oral medication, inability or unwillingness to comply with the
             drug administration requirements, or gastrointestinal (GI) procedure that could
             interfere with the oral absorption or tolerance of treatment.

         17. Treatment with any investigational products within 30 days before randomization.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>23/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>761</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/07/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Fitzroy</hospital>
    <hospital> - Frankston</hospital>
    <postcode> - Fitzroy</postcode>
    <postcode> - Frankston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Temuco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Grad Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Rijeka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Kralovehradecky kraj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Arhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Holstebro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Attiki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Ioannina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kobe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagoya-City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tachikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Toyohashi-city</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mazowieckie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Slaskie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Almada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kirov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Pyatigorsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Murcia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Sodermanlands lan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Vastra Gotalands lan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oldham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Millennium Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effect of ixazomib maintenance therapy on
      progression free survival (PFS) compared with placebo, in participants with newly diagnosed
      multiple myeloma (NDMM) who have had a major response (complete response [CR], very good
      partial response [VGPR], or partial response [PR]) to initial therapy and who have not
      undergone stem-cell transplantation (SCT).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02312258</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director Clinical Science</name>
      <address>Millennium Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Takeda Study Registration Call Center</name>
      <address />
      <phone>+1-844-662-8532</phone>
      <fax />
      <email>globaloncologymedinfo@takeda.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>